Skip to content

Chelsea Therapeutics International, Ltd.

Delisted

CIK 1333763fmd_0RCAWRZK63CVER9W73PGBJHSNYManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2004 to Mar 31, 2014, 22 periods

Latest annual · FY2013

Millions
Operating income
(16)
Net income
(16)
Free cash flow
(15)

Latest quarter · Q1 FY2014

Millions
Operating income
(8)
Net income
(8)
Free cash flow
(7)
Open Financials

Key stats

Open Analysis

Compound annual growth

Net income, 5 yearsFY2008 to FY2013
n/m

Chelsea Therapeutics International, Ltd. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2013FY2012ChangeSource
Operating income-$16.4 million-$31.8 million10-K 2014-03-11 · proof
Net income-$16.4 million-$31.7 million10-K 2014-03-11 · proof
Cash from operating activities-$15 million-$39.4 million10-K 2014-03-11 · proof
Free cash flow-$15 million-$39.4 million10-K 2014-03-11 · proof
Total assets$46.5 million$28.9 million+60.8%10-K 2014-03-11 · proof
Total liabilities$3.2 million$3 million+7.8%10-K 2014-03-11 · proof
Cash and cash equivalents$45.3 million$28.4 million+59.4%10-K 2014-03-11 · proof
What was Chelsea Therapeutics International, Ltd.'s operating income in fiscal 2013?
Chelsea Therapeutics International, Ltd. reported operating income of -$16.4 million for fiscal 2013 (the year ended Dec 31, 2013), against -$31.8 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2014. SEC
What was Chelsea Therapeutics International, Ltd.'s net income in fiscal 2013?
Chelsea Therapeutics International, Ltd. reported net income of -$16.4 million for fiscal 2013 (the year ended Dec 31, 2013), against -$31.7 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2014. SEC
What was Chelsea Therapeutics International, Ltd.'s cash from operating activities in fiscal 2013?
Chelsea Therapeutics International, Ltd. reported cash from operating activities of -$15 million for fiscal 2013 (the year ended Dec 31, 2013), against -$39.4 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2014. SEC
What was Chelsea Therapeutics International, Ltd.'s free cash flow in fiscal 2013?
Chelsea Therapeutics International, Ltd. reported free cash flow of -$15 million for fiscal 2013 (the year ended Dec 31, 2013), against -$39.4 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2014. SEC
What are Chelsea Therapeutics International, Ltd.'s total assets?
As of Dec 31, 2013, Chelsea Therapeutics International, Ltd. reported total assets of $46.5 million, against $28.9 million a year earlier (+60.8%). Source: the 10-K filed with the SEC on Mar 11, 2014. SEC
What are Chelsea Therapeutics International, Ltd.'s total liabilities?
As of Dec 31, 2013, Chelsea Therapeutics International, Ltd. reported total liabilities of $3.2 million, against $3 million a year earlier (+7.8%). Source: the 10-K filed with the SEC on Mar 11, 2014. SEC
What are Chelsea Therapeutics International, Ltd.'s cash and cash equivalents?
As of Dec 31, 2013, Chelsea Therapeutics International, Ltd. reported cash and cash equivalents of $45.3 million, against $28.4 million a year earlier (+59.4%). Source: the 10-K filed with the SEC on Mar 11, 2014. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1333763&period_type=annual&limit=5"

Information only, not investment advice.